288 results on '"Négrier S"'
Search Results
2. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
3. HSD117 Healthcare Resources Utilization (HCRU) and Exploration of the Patient Journey through Claims Database: An Application on Advanced Renal Cell Carcinoma (ARCC) Patients in France
4. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
5. Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?
6. EE171 Hospital Costs of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Undergoing Radical Surgery: A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)
7. P37 Impact of Method for Modelling Distant Recurrence (DR) on Cost-Effectiveness (CE) of Nivolumab (NIVO) as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients With High Risk of Recurrence in France
8. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
9. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial
10. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
11. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
12. Interleukin-2 Therapy: Report on 129 Patients and Three Different Schedules
13. Clinical application of gene transfer in oncology: preliminary results of a French study
14. Les essais cliniques français GETUG et AFU en cours concernant les carcinomes urothéliaux et les cancers du rein et de prostate
15. Cancer du rein métastatique : bilan préthérapeutique, instauration et suivi d’un traitement anti-angiogénique. À propos d’un cas
16. Stimulation of the Immune System for the Therapy of Advanced Stage Neuroblastoma
17. Adoptive Immunotherapy with IL-2 in 27 Patients with Metastatic Renal Cell Carcinoma
18. Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2–3 Months Post ABMT
19. rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma
20. Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
21. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
22. 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
23. 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
24. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
25. 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial
26. Temsirolimus in metastatic renal cell carcinoma
27. 1472P Biomarkers of the response in metastatic papillary renal cell carcinoma
28. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
29. 1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
30. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie
31. Immunotherapy in metastatic renal cell cancer. The Lyon’s experience on 100 patients
32. First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts’ Prescribing Practices and Systematic Literature Review
33. PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
34. Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma
35. Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
36. Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinoma
37. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
38. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
39. Standards, Options et Recommandations pour la radiothérapie du cancer du rein
40. Mise en place de fiducials surrénaliens sous contrôle écho-endoscopique (EE) et radioscopique avant radiothérapie stéréotaxique (RTS): intérêt, faisabilité et sécurité à propos de 6 cas consécutifs (Première série rapportée)
41. Kidney
42. 1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
43. 1323P - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
44. 966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma
45. 947P - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): Final results
46. 909PD - NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
47. 908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
48. LBA6_PR - JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
49. 1306TiP - ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
50. 870PD - Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.